Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Sells Protein Array Business to Aushon

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has sold its SearchLight Protein Array business and technology assets to Aushon BioSystems for an undisclosed amount.

Billerica, Mass.-based Aushon will integrate the SearchLight business but will continue to offer products under the SearchLight brand, it said today.

Aushon, which sells microarray instruments and related consumables for genomic and proteomic applications, gains several products and service capabilities through the deal. Among SearchLight's products are custom protein arrays, chemiluminescent and infrared assay kits, and a CCD imaging and analysis system for immunoassays. SearchLight also offers a custom service that allows researchers to submit samples for quantitative analysis using the firm's biomarker arrays.

"With the addition of the SearchLight technology platform and its products and services, we can now offer our clients a virtual one-stop shop for their biomarker research needs — from microarray printing and custom assay development to biomarker testing services in a CLIA-certified laboratory," Peter Honkanen, CEO of Aushon, said in a statement.

Aushon said that it expects the acquisition will enable it to accelerate biomarker research in preclinical and clinical studies for pharmaceutical, biotech, and diagnostic customers.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.